Featured Publications
High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes. Cancer Discov. 1 May 2025; 15 (5):969–987. https://doi.org/10.1158/2159-8290.CD-24-1509
Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels. Nat Commun. 2025 Oct 14;16(1):9122. doi: 10.1038/s41467-025-64153-z. PMID: 41087333; PMCID: PMC12521513.
Helzer KT, Sharifi MN, Sperger JM, Shi Y, Annala M, Bootsma ML, Reese SR, Taylor A, Kaufmann KR, Krause HK, Schehr JL, Sethakorn N, Kosoff D, Kyriakopoulos C, Burkard ME, Rydzewski NR, Yu M, Harari PM, Bassetti M, Blitzer G, Floberg J, Sjöström M, Quigley DA, Dehm SM, Armstrong AJ, Beltran H, McKay RR, Feng FY, O’Regan R, Wisinski KB, Emamekhoo H, Wyatt AW, Lang JM, Zhao SG. Fragmentomic analysis of circulating tumor DNA-targeted cancer panels. Ann Oncol. 2023 Sep;34(9):813-825. doi: 10.1016/j.annonc.2023.06.001. Epub 2023 Jun 16. PMID: 37330052; PMCID: PMC10527168.
Kauffman ZJ*, Koesser K*, Helzer KT, Sharifi MN, Heninger E, Li C, Juang DS, Jarrard DF, Zhao SG, Haffner MC, Beebe DF, Lang JM, Sperger JM. Lossless Altered Histone Modification Analysis System (LAHMAS). *Contributed equally. Lab Chip. 2025 Jul 7. doi: 10.1039/d5lc00060b. Online ahead of print. PMID: 40620045.
Sánchez-de-Diego C, Yada RC, Sethakorn N, Geiger PG, Ding A, Heninger E, Ahmed F, Virumbrales-Muñoz M, Lupsa N, Bartels E, Stewart K, Ponic SM, Sharifi MN, Lang JM, Beebe DJ, Kerr SC. Engineering the bone metastatic prostate cancer niche: a microphysiological system to report patient-specific treatment response. Commun Biol. 2025 Jul 1;8(1):961. doi: 10.1038/s42003-025-08384-2. PMID: 40596459.
Sharifi MN, Heninger E, Bootsma ML, Recchia EE, Breneman MT, Taylor AK, Zhao SG, LeBeau AM, Kosoff D. Transcriptomic signatures of monocyte-derived macrophages associate with androgen receptor pathway inhibitor progression in prostate cancer. Prostate. 2025 Jul 2. doi: 10.1002/pros.70000. Online ahead of print. PMID: 40605246.
Feng E, Feng E, Berg T, Nguyen IS, Nguyen LG, Chen W, Zhang M, Quigley D, Sharifi M, Li H, Coleman I, Nelson PS, Sjöström M, Zhao SG. Identifying prognostic targets in metastatic prostate cancer beyond AR. FEBS Open Bio. 2025 May 22. doi: 10.1002/2211-5463.70059. Epub ahead of print. PMID: 40405591.
Sharifi MN, Feng E, Rydzewski N, Taylor AK, Sperger JM, Shi Y, Helzer KT, Bootsma M, Carreno V, Chang AC, Nunamaker L, Blitzer G, Shang TA, Subramanian A, Bjartell A, Josefsson A, Wilkstrom P, Feng E, Kohli M, Yang R, Dehm SM, Small EJ, Aggarwal R, Quidley DA, Lang JM, Zhao SG, Sjöström M. Adverse Prognosis Gene Expression Patterns in Metastatic Castration-Resistant Prostate Cancer. Molecular Oncology. 2025 Feb 22. doi: 10.1002/1878-0261.70001. Epub ahead of print. PMID: 39985777.
Young KS, Hancock GR, Fink E, Zigrossi A, Flowers B, Cooper DA, Nguyen VT, Martinez M, Mon KS, Bosland M, Zak D, Runde A, Sharifi MN, Kastrati I, Minh DDL, Kregel S, Fanning SW. Targeting Unique Ligand Binding Domain Structural Features Downregulates DKK1 in Y537S ESR1 Mutant Breast Cancer Cells. Breast Cancer Research. 2025 Jan 17;27(1):10. doi: 10.1186/s13058-024-01945-z. PMID: 39825366; PMCID: PMC11742495.
Miyahira AK, Sharifi M, Chesner LN, El-Kenawi A, Haas R, Sena LA, Tewari AK, Pienta KJ, Soule HR. Personalized Medicine: Leave no Patient Behind; Report From the 2024 Coffey-Holden Prostate Cancer Academy Meeting. Prostate. 2025 Feb;85(3):211-226. doi: 10.1002/pros.24826. Epub 2024 Nov 27. PMID: 39604057
Heninger E, Breneman MT, Recchia EE, Kerr SC, Dogru RE, Sharifi MN, LeBeau AM, Kosoff D. Dynamic reciprocal interactions between activated T cells and tumor associated macrophages drive macrophage reprogramming and proinflammatory T cell migration within prostate tumor models. Sci Rep. 2024 Oct 16;14(1):24230. doi: 10.1038/s41598-024-75265-9. PMID: 39414902
Bakhtiar H*, Sharifi MN*, Helzer KT, Shi Y, Bootsma ML, Shang TA, Chrostek M, Berg T, Callahan SC, Carreno V, Blitzer GC, West MT, O’Regan, RM, Wisinski KB, Sjöström M, Zhao SG. A Phenocopy Signature of TP53 Loss Predicts Response to Chemotherapy. NPJ Precision Oncology, NPJ Precis Oncol. 2024 Oct 2;8(1):220. doi: 10.1038/s41698-024-00722-7. PMID: 39358429. *Contributed equally.